Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options

Aurora Cannabis

Canopy Growth

GW Pharmaceuticals

HEXO Corp

The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?

Is This a Buying Opportunity in the Marijuana Stocks?

ACADIA Pharma

Biogen

BioXcel Therapeutics

Cortexyme Inc

Intra-Cellular Therapies

Neurocrine Biosciences

SAGE Therapeutics

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Canaccord Genuity’s Top Biopharma Catalysts for the Rest of 2020

Axcella Health Inc

Fly Leasing

Federal Home Loan Mortgage Corporation

Federal National Mortgage Association

GasLog

Green Plains Partners

Precigen

Synchronoss

The stock market’s fall from February through March was monumental, bringing on the fastest bear market we have seen in our lives.

8 Stocks That Could Double From 2020 to 2021, With No COVID-19 Focus at All

- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist -

Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial -

Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

DEVON, Pa., May  26, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life results of the Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial. These data are being presented at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session. The Virtual Session is online at http://www.aan.com/2020science. A copy of the posters are also available on the Zynerba corporate website at http://zynerba.com/publications/ . The top line results of the 26-week Phase 2 BELIEVE trial were initially announced in September 2019. (Press release)

Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

Is  (ZYNE) Outperforming Other Medical Stocks This Year?

Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

- New Data Presented Today at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - New Data Presented Today at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting -

Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

Zynerba Pharmaceuticals (ZYNE) closed at $4.18 in the latest trading session, marking a -1.88% move from the prior day.

Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know

Topline Results are expected late in the Second Quarter of 2020 Topline Results are expected late in the Second Quarter of 2020

Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

DEVON, Pa., Feb.  25, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,568,848, titled “Treatment of Autism with Cannabidiol” which includes claims directed to methods of treating autism spectrum disorder (ASD) by transdermally administering, via a gel or cream, a therapeutically effective amount of purified cannabidiol (CBD).

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol

Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zynerba Pharmaceuticals Enters Oversold Territory

- Company Expects to Complete Randomization in February 2020 -

Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome

Arena Pharmaceuticals

Cara Therapeutics

Corbus Pharmaceuticals Holdings

Cronos Group

Greenlane Holdings

Marrone Bio Innovations

New Age Beverages

Intec Parent

OrganiGram Holdings Inc.

Psychemedics

SNDL Inc.

Tilray Brands

Therapix Biosciences

Village Farms International

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.

Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

– Company Confirms Expectation of Topline Results in the Second Quarter of 2020 – – Company Confirms Expectation of Topline Results in the Second Quarter of 2020 –

Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

- Topline Results from BRIGHT Study Expected in the Second Quarter of 2020 - - Topline Results from BRIGHT Study Expected in the Second Quarter of 2020 -

Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

Aphria

Here we discuss three best stocks in the emerging cannabis space.

Ride the Cannabis Wave With These 3 Stocks

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares ended Monday's session nearly 15% higher after Canaccord Genuity said the stock's mid-September sell-off was unjustified.

Zynerba Analyst Says Stock A Buy Ahead Of Zygel Data Release In 2020

Bausch Health Companies Inc

Teva Pharmaceutical

Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.

Generic Drugmakers Gain as Price-Fixing Probe Nears an End

DEVON, Pa., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Vice President of Communications and Investor Relations, Will Roberts, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference. The presentation will take place on Tuesday, October 29th at 9:40AM EDT at the Wyndham Grand Jupiter. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.  

Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Amarin Corporation Plc

Celsius Holdings

eHealth

Green Thumb Industries Inc.

Health Insurance Innovations

OptiNose

Investors are looking for the stocks that have the potential to lift their portfolios to new heights.

7 Stocks to Buy With 100% Upside Potential

In a dismal year for most marijuana stocks, these three winners have bucked the trend.

3 Best Pot Stocks So Far This Year in the Biggest Marijuana ETF

News for Zynerba Pharmaceuticals Stock (ZYNE)